戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  to 2 who were planned to receive first-line palliative therapy.
2 sfunction, reirradiation largely serves as a palliative therapy.
3 lly "unresectable" for cure and treated with palliative therapy.
4 dysfunction of secretory epithelia with only palliative therapy.
5           There is no treatment for EB, only palliative therapy.
6  have made a positive impact on curative and palliative therapy.
7 rrence and no survival benefit compared with palliative therapy.
8 liver transplantation candidacy, and role of palliative therapy.
9 liver transplantation candidacy, and role of palliative therapy.
10 e is currently no effective treatment except palliative therapy.
11 ncer (28% reduction), 14 fewer men receiving palliative therapy (35% reduction), and a total of 73 li
12 ophylaxis late in the course of curative and palliative therapy (80% v 53%); and (3) treatment of afe
13 ium-90-loaded microspheres is an established palliative therapy and can be considered a "curative int
14 rostate carcinoma who received 89Sr-chloride palliative therapy and from 10 age-matched healthy volun
15 andomized trials of first-line, salvage, and palliative therapy and the role of surgery after chemoth
16 s in treatment allocation (curative therapy, palliative therapy, and best supportive care) between pa
17 onally practiced involves the institution of palliative therapy as the disease progresses at a time w
18 se-intensive regimens either for curative or palliative therapy became more common.
19 s were treated with multimodality therapy or palliative therapy because of contraindications for tran
20 ysfunction defies elucidation, and thus only palliative therapy exists.
21 ons confer survival advantages compared with palliative therapies for hepatocellular carcinoma (HCC),
22                   The frontier of endoscopic palliative therapies for pancreatic adenocarcinoma is ex
23                               Historically a palliative therapy for advanced liver cancer, TARE with
24 he decision was likely preference-sensitive (palliative therapy for metastatic cancer), and treatment
25 imum, BRAF inhibitors seem to be valuable as palliative therapy for metastatic melanoma.
26 nhibitor (MKI) sorafenib can be an effective palliative therapy for patients with hepatocellular carc
27           Oncologists may use this to tailor palliative therapy for patients.
28  be a useful target for either preventive or palliative therapy for periodontitis.
29 sarterial chemoembolization and sorafenib as palliative therapy have improved the outlook for HCC pat
30 g the pathogenesis of AD, the development of palliative therapies is still lacking.
31 asis for atrial fibrillation is unknown, and palliative therapy is used to control the ventricular ra
32 is occurs, there are no curative options and palliative therapy is usually indicated.
33 of brain metastases was considered a form of palliative therapy only, but more recently it has been s
34  treatments, most patients currently receive palliative therapies with steroid molecules such as pred
35 ssociated with cost-effectiveness studies of palliative therapy, with emphasis on the problem of calc